How we do R&D
Xổ số miền nam thứ 7 tuần trướcHealthcare research has never been more important. Time and time again, our research and development (R&D) has resulted in products that have advanced the understanding of disease and transformed the practice of medicine. This has always been the lifeblood of our company, and our substantial investment in R&D reflects that.
Having Diagnostics and Pharmaceuticals in one company is a powerful advantage that sets Roche apart. Close cooperation between the two is central to our personalised healthcare strategy. Although they have different R&D processes, the two divisions share expertise, research facilities and technologies when working together on projects.
At the same time, we believe that diversity in scientific thinking will produce the innovations in healthcare so desperately needed by society. That’s why we maintain three, independently-operated Pharma R&D units, alongside a strong network of more than 150 external partner organisations.
Xổ số miền nam thứ 7 tuần trướcPharma Research and Early Development (pRED), Genentech Research and Early Development (gRED), and Chugai in Japan provide this diversity of scientific approach, as well as enabling access to expertise, new technologies and promising drug candidates.
Roche Pharma Research and Early Development (pRED)
Genentech Research and Early Development (gRED)
Chugai Pharmaceuticals, a member of the Roche Group
R&D in Six Diagnostics Business Areas
A healthcare pioneer and the industry’s global leader in in-vitro diagnostics, the Diagnostics Division pushes boundaries and challenges the status quo to redefine what’s possible. Our commitment to research and development means we can bring to the market integrated solutions in diagnostic testing, laboratory efficiency, healthcare digitalisation and decision support tools and software. Our products deliver increasingly precise information to help save lives, prevent or control the risk of infection and monitor treatment effectiveness.
The Roche Diagnostics Business Areas include Centralised and Point of Care Solutions (CPS), Molecular Diagnostics, Tissue Diagnostics, Sequencing, Diagnostics Information Solutions (DIS), and Diabetes Care. We have R&D facilities in the United States, Austria, Germany, Poland, Switzerland, South Africa and China.
Comprehensive solutions to meet your molecular testing needs
Clinical decision support transforms data into actionable insights
Xổ số miền nam thứ 7 tuần trướcOur goal in DIS is to redefine how data drives patient care and R&D to help ensure the right treatment reaches the individual patient at the right time.more